Emcure Pharmaceuticals’ shares to debut on stock exchanges with a GMP of Rs 360. Analysts bullish on both short-term and long-term gains. Company aims to use IPO proceeds to reduce debt and boost growth. Revenue grows 11% in FY24 while profit dips 6%.
| Subscribe To Our Free Newsletter |
